The XINDI Study: A Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Safinamide as Add-On Therapy to Levodopa in Chinese Patients with Parkinson’s Disease with Motor Fluctuations

BACKGROUND: Levodopa remains the gold standard for the treatment of Parkinson’s disease, but its long-term use is associated with motor complications whose management is still a significant challenge. Safinamide is a multimodal drug with proven efficacy as an adjunct to levodopa. OBJECTIVE: The obje...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Qianqian, Tan, Yuyan, Xu, Pingyi, Tao, Enxiang, Lu, Zuneng, Pan, Xiaoping, Wang, Baojun, Liu, Chunfeng, Dong, Xueshuang, Tian, Yuling, Sun, Xin, Cattaneo, Carlo, Chen, Shengdi, Shang, Huifang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9641300/
https://www.ncbi.nlm.nih.gov/pubmed/36346534
http://dx.doi.org/10.1007/s40263-022-00958-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9641300/
https://www.ncbi.nlm.nih.gov/pubmed/36346534
http://dx.doi.org/10.1007/s40263-022-00958-6

Ejemplares similares